Latest Conference Articles

September 11th 2019, 1:37am

IASLC World Conference on Lung Cancer

David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.

September 11th 2019, 1:27am

IASLC World Conference on Lung Cancer

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

September 11th 2019, 1:02am

IASLC World Conference on Lung Cancer

Targeted therapies for non­–small cell lung cancer produced mixed results in a novel multiarm clinical trial that matched tumor mutations to drugs targeting the mutations.

September 10th 2019, 9:31pm

IASLC World Conference on Lung Cancer

The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer.

September 10th 2019, 7:25pm

IASLC World Conference on Lung Cancer

Treatment with nivolumab (Opdivo) was associated with a 5-year overall survival rate of 13.4% compared with 2.6% with docetaxel in patients with previously treated non–small cell lung cancer.

September 10th 2019, 1:46am

IASLC World Conference on Lung Cancer

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

September 10th 2019, 1:45am

IASLC World Conference on Lung Cancer

Corey J. Langer, MD, director, thoracic oncology, Penn Medicine, discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

September 10th 2019, 1:20am

IASLC World Conference on Lung Cancer

Anna F. Farago, MD, PhD, assistant professor of medicine, Harvard Medical School, discusses the updated activity of larotrectinib in NTRK fusion–positive lung cancer.

September 10th 2019, 12:20am

IASLC World Conference on Lung Cancer

Almost 70% of patients with previously treated RET-fusion–positive non–small cell lung cancer had objective responses to the RET inhibitor selpercatinib (LOXO-292), according to data from the phase I/II LIBRETTO-001 trial presented at the 2019 World Conference on Lung Cancer.

September 9th 2019, 9:44pm

IASLC World Conference on Lung Cancer

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

September 9th 2019, 1:53am

IASLC World Conference on Lung Cancer

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

September 9th 2019, 1:35am

IASLC World Conference on Lung Cancer

Pasi A. Jänne, MD, PhD, discusses 3 studies of novel agents for targeting EGFR-mutant and HER2-positive lung cancers and the next steps in getting the research to cancer clinics.

September 8th 2019, 7:54pm

IASLC World Conference on Lung Cancer

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

July 28th 2019, 1:00am

International Lung Cancer Congress

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.

July 28th 2019, 12:37am

International Lung Cancer Congress

Heather A. Wakelee, MD, professor of medicine (oncology), Stanford University Medical Center, discusses osimertinib and its role in treating patients with EGFR-mutant non–small cell lung cancer.

July 27th 2019, 11:14pm

International Lung Cancer Congress

With the arrival of immunotherapy to the small cell lung cancer armamentarium, combination approaches with targeted therapies are now in the pipeline to stimulate further clinical activity, such as adding PARP or CHK1 inhibitors.

July 27th 2019, 11:05pm

International Lung Cancer Congress

The magnitude of data becoming available on immunotherapy combinations for patients with non–small cell lung cancer has made treatment selection complicated.

July 27th 2019, 7:20pm

International Lung Cancer Congress

The early potential shown with the KRAS inhibitor AMG 510 coupled with several promising ongoing combination studies has ushered in the beginning of an exciting era for the treatment of KRAS-mutant non–small cell lung cancer.

July 27th 2019, 5:22am

International Lung Cancer Congress

Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.

July 27th 2019, 5:15am

International Lung Cancer Congress

Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology, professor of the Department of Hematology/Oncology, and co-director of the Immune Monitoring Facility at Fox Chase Cancer Center, discusses recent announcements from the CheckMate-227 trial in non–small cell lung cancer.